pharmacokinetic PK

Related by string. pharmacokinetics PK * Pharmacokinetics . Pharmacokinetic . pharmacokinetics : safety tolerability pharmacokinetics . safety tolerability pharmacokinetic . favorable pharmacokinetic profile . tolerability pharmacokinetics / PKS . PKs . Pk : Lt Gen PK Rath . PK Banerjee . PK Narayana Panicker * pharmacokinetic PK study . pharmacokinetic PK profile . formal pharmacokinetic PK *

Related by context. All words. (Click for frequent words.) 78 pharmacodynamic PD 73 Pharmacokinetic 73 pharmacokinetics PK 72 Phase 1a clinical 72 pharmacokinetic PK study 72 phase Ib 71 Phase Ib study 71 Phase 2a trial 71 fosbretabulin 71 Pharmacokinetic PK 71 viral kinetic 71 Phase 2a clinical 70 GAMMAGARD 70 safety tolerability pharmacokinetic 70 pharmacodynamic effects 70 BRIM3 70 Phase 1b 70 pharmacokinetic PK profile 70 favorable pharmacokinetic profile 70 preclinical efficacy 70 Phase IIa clinical 70 multicenter Phase II 70 Phase 1a 70 pharmacodynamic 69 Phase Ib clinical 69 multicentre randomized 69 Pharmacodynamic 69 Phase 2b study 69 Azedra 69 alvespimycin 69 pharmacodynamics PD 69 Phase Ib 69 phase IIa clinical 69 ongoing Phase 1b 69 phase IIb 68 pharmacokinetic 68 nonrandomized 68 prospectively defined 68 Phase Ib II 68 BRIM2 68 Phase 2a 68 MEND CABG 68 riociguat 68 randomized Phase 2b 68 TOLAMBA 68 INCB# [001] 68 teriflunomide 67 MERLIN TIMI 67 pharmacodynamic endpoints 67 SPIRIT FIRST 67 PRTX 67 plasma pharmacokinetics 67 phase IIa 67 STRIDE PD 67 Phase 1b trial 67 oral prodrug 67 pharmacokinetics pharmacodynamics 67 pharmacodynamic properties 67 dose escalation Phase 67 pharmacokinetic pharmacodynamic 67 investigational humanized monoclonal antibody 67 Traficet EN 67 phase IIb clinical 67 CR# vcMMAE 67 crizotinib PF # 67 ganetespib 67 maximally tolerated dose 67 Phase IIIb clinical 67 phase 2a 67 Phase #/#a 67 HuMax EGFr 67 RE LY ® 67 prucalopride 67 TMC# C# 67 elotuzumab 66 neratinib 66 varespladib 66 pharmacokinetic parameters 66 tolerability pharmacokinetics 66 Phase IIB 66 phase IIb study 66 MEND CABG II 66 Pharmacokinetics PK 66 viral kinetics 66 ADAGIO study 66 prospective multicentre 66 RE LY 66 randomized Phase III 66 CLORETAZINE TM VNP#M 66 tanespimycin 66 pharmacokinetic studies 66 HGS ETR2 66 SYMMETRY trial 66 multicenter randomized placebo controlled 66 ENMD # 66 pharmacodynamic profiles 66 Primary endpoints 66 Phase 2b trial 66 orally bioavailable 66 ATL# [001] 66 biodistribution 66 confirmatory clinical 66 vidofludimus 66 desvenlafaxine succinate 66 placebo controlled clinical 66 FOLOTYN ® 66 dose escalation trial 66 tolerability profiles 66 ELACYT 66 vitro cytotoxicity 66 cobiprostone 66 trastuzumab emtansine T DM1 66 registrational 66 efficacy tolerability 66 SABCS 66 Enzastaurin 66 registrational trial 66 phase IIb trial 66 Phase IIa trial 66 anti leukemic 66 APTIVUS 66 forodesine 66 pharmacodynamic profile 65 randomized multicenter 65 Randomized Evaluation 65 QLT# 65 randomized controlled Phase 65 depsipeptide 65 GLYX 65 multicenter randomized controlled 65 pharmacodynamic markers 65 ADVANCE PD 65 preclinical pharmacokinetic 65 APPRAISE 65 Denufosol 65 liposomal formulation 65 Androxal TM 65 BAL# [002] 65 secondary efficacy endpoints 65 evaluating tivozanib 65 Chemophase 65 EOquin TM 65 pharmacokinetic profile 65 ascending dose 65 Phase 1b clinical 65 Phase #b/#a 65 noninferiority 65 Zenvia Phase III 65 Apoptone 65 Phase IIb III 65 CANCIDAS 65 Triolex 65 Phase 2b clinical 65 placebo controlled Phase 65 ISIS # 65 galiximab 65 IMA# 65 pharmacokinetic characteristics 65 CHAMPION PCI 65 dose proportionality 65 LibiGel ® 65 velafermin 65 LAB CGRP 65 Phase IIb clinical 65 p# biomarker 65 pertuzumab 65 JAK inhibitor 65 PRT# 65 GMX# 65 CEQ# 65 antiviral efficacy 65 Archexin 65 solithromycin 65 EDEMA3 trial 65 PXD# 65 Tyrima 65 GLP toxicology studies 65 HGS ETR1 65 Prospective Randomized 65 SCH # 65 tolerability 65 ORMD 65 Phase Ia 65 Lp PLA 2 65 torezolid phosphate 65 dose escalation study 65 PRIMO CABG2 65 analgesic efficacy 65 Kahalalide F 64 pomalidomide 64 Xanafide 64 indibulin 64 NP2 Enkephalin 64 CINQUIL 64 randomized discontinuation trial 64 trodusquemine 64 enzastaurin 64 ABSORB trial 64 Phase IIa 64 demonstrated clinically meaningful 64 Phase IIIb 64 pharmacodynamic parameters 64 pharmacodynamics 64 dose cohort 64 Pivotal Phase III 64 GRNCM1 64 NOX E# 64 CCX# 64 RG# [001] 64 nonclinical studies 64 Phase III Clinical Trial 64 phase IIIb 64 eprotirome 64 AZILECT R 64 dose escalation phase 64 prospective multicenter randomized 64 Antiviral Activity 64 immunogenicity 64 Acute Ischemic Stroke 64 melphalan prednisone 64 Edge STudy 64 prospective multicenter 64 RSD# oral 64 NO# [002] 64 IMPACT DCM 64 nab paclitaxel 64 Randomized Double blind 64 Pralatrexate 64 huC# DM4 64 dose escalation clinical 64 Cloretazine ® 64 QTc prolongation 64 PS# [001] 64 TPI ASM8 64 multicenter Phase 64 PDX pralatrexate 64 mg/m2 cohort 64 randomized Phase IIb 64 Initiated Phase 64 pharmacokinetic profiles 64 blinded randomized placebo controlled 64 XmAb# 64 LUX Lung 64 HORIZONS AMI trial 64 SYNTAX trial 64 dose cohorts 64 AeroLEF TM 64 Amrubicin 64 Randomized Phase 64 rHuPH# 64 placebo controlled Phase III 64 pharmacokinetics 64 huN# DM1 64 CA4P 64 Bezielle 64 PRE SURGE 64 IIa trial 64 multiple ascending dose 64 sitaxsentan 64 PRIMO CABG 64 Phase #b/#a trial 64 Tarceva TM 64 PCI ExTRACT TIMI 64 histone deacetylase inhibitor 64 GFT# 64 cannabinor 64 clevidipine 64 HCV SPRINT 64 subgroup analyzes 64 temsirolimus Torisel ® 64 ritonavir boosted 64 Urocortin 2 64 PEG SN# 64 RE SURGE 64 novel histone deacetylase 64 Trofex 64 LB# [003] 64 EURIDIS 64 ALN TTR# 64 lintuzumab 64 MGd 64 Sym# 63 double blinded placebo 63 CYT# 63 davunetide intranasal AL 63 CIMZIA ™ 63 ExTRACT TIMI 63 REG2 63 assessing T DM1 63 ACAPODENE 63 IMC A# 63 EGFR HER2 63 efficacy endpoint 63 rALLy trial 63 Quinamed 63 EDEMA3 63 radiation dosimetry 63 Ranolazine 63 ON #.Na 63 ZYBRESTAT fosbretabulin 63 Carfilzomib 63 oral ridaforolimus 63 TAXUS ATLAS 63 CIMZIA TM 63 RE LY trial 63 prospective multicenter study 63 subcutaneous SC 63 erythropoietic 63 Exherin TM 63 thorough QT 63 teduglutide 63 mertansine 63 CoFactor 63 Phase III psoriasis 63 II Clinical Trial 63 tolerated dose MTD 63 HDL Selective Delipidation 63 EVEREST II 63 trastuzumab DM1 T DM1 63 APTIVUS r 63 Golimumab 63 denufosol 63 Zemplar Capsules 63 active comparator 63 GOUT 63 UPLYSO 63 ENDEAVOR IV 63 PFO migraine 63 trials RCTs 63 tolerability profile 63 relapsed MM 63 guanfacine extended release 63 prospective randomized multicenter 63 Vernakalant 63 systemically administered 63 lorvotuzumab mertansine 63 topoisomerase II inhibitor 63 intravenous dosing 63 HCV RESPOND 2 63 PRECiSE 63 dosage regimens 63 surrogate endpoint 63 Phase #b/#a clinical 63 novel VDA molecule 63 imetelstat 63 achieved statistical significance 63 ROCKET AF 63 lucinactant 63 multicenter Phase III 63 AIR# [001] 63 CBLC# 63 R#/MEM # 63 BOLDER II 63 subcutaneously administered 63 oral rivaroxaban 63 Phase #/#a trial 63 dosing cohort 63 YONDELIS 63 PDE4 inhibitor 63 DAVANAT 63 PSN# [002] 63 KRN# 63 sulodexide 63 EGS# 63 multicenter prospective 63 dose limiting toxicities 63 Zenvia ™ 63 lomitapide 63 SAR# [004] 63 Aplidin R 63 rilonacept 63 elacytarabine 63 RDEA# 63 IIa trials 63 elagolix 63 Tolerability 63 Ambrisentan 63 NSABP B 63 immunohistochemical 63 fallopian tube cancers 63 Capesaris 63 epoetin alpha 63 ataluren 63 HER2 positive metastatic breast 63 placebo controlled dose escalation 62 Cloretazine 62 PSMA ADC 62 blinded randomized 62 Squalamine 62 Plenaxis TM 62 CLIRS 62 SUCCEED trial 62 glufosfamide 62 Phase 1b clinical trials 62 intravesical 62 DLTs 62 alagebrium 62 obatoclax 62 CTAP# Capsules 62 Virulizin ® 62 clinical pharmacology studies 62 MoxDuo IR 62 Echocardiographic 62 multicenter placebo controlled 62 pharmacokinetic properties 62 CIMZIA TM certolizumab pegol 62 PREVENT IV 62 confirmatory Phase III 62 Secondary efficacy endpoints 62 Clinical Trial Results 62 basal bolus regimen 62 Clinical Antipsychotic Trials 62 ularitide 62 Phase III Clinical Trials 62 CDK inhibitor 62 HQK 62 budesonide foam 62 Aplidin 62 AVOREN 62 IL #E 62 Onrigin 62 multicenter phase 62 PHX# 62 masked placebo controlled 62 OXi# 62 receptor tyrosine kinase inhibitor 62 DermaVir Patch 62 peripheral blood mononuclear 62 SERCA2a 62 Phase 2b 62 CALGB # [002] 62 prospective randomized controlled 62 Immunogenicity 62 delafloxacin 62 MAGE A3 ASCI 62 CRLX# 62 F FDG PET 62 OncoVEX GM CSF 62 Phase III randomized controlled 62 antitumor activity 62 LEXIVA r 62 ToGA 62 single ascending dose 62 IMPROVE HF 62 randomized controlled multicenter 62 subanalysis 62 Elagolix 62 Randomised 62 eniluracil 62 Valortim R 62 PANVAC VF 62 VP# [004] 62 Phase IIIb study 62 PD LID 62 Ophena TM 62 PREZISTA r 62 PREOS 62 IRX 2 62 LibiGel Phase III 62 AEG# 62 randomized blinded 62 HGS# 62 non nucleoside 62 recurrent glioblastoma multiforme 62 Phase Ib clinical trials 62 bazedoxifene conjugated estrogens 62 sunitinib malate 62 HIF PHI 62 Ocrelizumab 62 JAK2 V#F 62 refractory chronic lymphocytic 62 HuMax CD4 62 Phase III multicenter 62 MGN# 62 MAP# 62 PROPEL trial 62 vascular disrupting agent 62 Val HeFT 62 HER2 antibody 62 antiarrhythmic drug 62 antibody MAb 62 ISTODAX 62 Panzem R NCD 62 mRCC 62 satraplatin Phase 62 Phase III ALLEGRO 62 tasimelteon 62 efficacy endpoints 62 GSK# [001] 62 dose escalation 62 Phase III clinical 62 multicentric 62 RAV# 62 Pivotal Trial 62 bosentan 62 CRMD# 62 AIR2 Trial 62 BCIRG 62 multicenter clinical 62 IL# PE#QQR 62 LEP ETU 62 Cloretazine R 62 Pafuramidine 62 RELOVAIR ™ 62 Prostate AdenoCarcinoma Treatment 62 avosentan 62 ruxolitinib 62 rFIXFc 62 IFN α 62 Proellex TM 62 Phase 2b Clinical Trial 62 aclidinium bromide 62 Elocalcitol 62 Pre RELAX AHF 62 randomized multicenter trial 62 PROSTVAC TM 62 antitumor effect 62 preclinically 62 axitinib 62 mITT population 62 uricase 62 rNAPc2 62 APEX AMI trial 62 Pharmacokinetic parameters 62 oral FTY# 62 pain palliation 62 PK PD 62 urinary N telopeptide 62 XIENCE V PROMUS Stent 62 APTIMA HPV 62 Valortim 62 Anturol TM 62 Deforolimus 62 Valortim ® 62 PKC# 62 C1 INH 62 Cloretazine R VNP#M 62 metastatic HRPC 62 Aurexis 62 GAP #B# 62 vernakalant hydrochloride 62 AVADO 62 inhaled iloprost 62 icatibant 62 VAPRISOL 62 AP# [003] 62 ZYBRESTAT 62 Pharmacokinetic Study 62 Phase IIb trials 62 Targretin 62 hematological parameters 62 hENT1 62 ACTEMRA 62 Ceplene/IL-2 62 systemic RNAi therapeutic 62 ATL/TV# 62 NCIC CTG 62 Plicera 62 COU AA 62 Vitaxin 62 mGluR5 NAM 61 demonstrated antitumor activity 61 ZOLINZA 61 histone deacetylase HDAC inhibitor 61 generation purine nucleoside 61 RECIST Response Evaluation Criteria 61 Ophena 61 limiting toxicity DLT 61 FOLPI 61 MIRCERA 61 randomized multicenter Phase III 61 mCRC patients 61 exploratory endpoints 61 PIX# [002] 61 TAXUS VI 61 Ozarelix 61 Meta analyzes 61 Multiple Ascending Dose 61 safety tolerability pharmacokinetics 61 AZX# 61 micafungin 61 Cimzia TM 61 Curaxin CBLC# 61 PERSEUS 61 tumorigenicity 61 Panzem R 61 paclitaxel poliglumex 61 Long Term Efficacy 61 xenograft models 61 Factor VIIa 61 OLYMPIA registry 61 selective modulator 61 sorafenib Nexavar 61 haematologic 61 Phase IIb clinical trials 61 Dapagliflozin 61 canakinumab 61 DSMB 61 alvimopan 61 ALN TTR 61 DXL# 61 administered subcutaneously 61 fluticasone furoate 61 XL# XL# XL# 61 TACI Ig 61 XL# SAR# 61 serum phosphorous 61 fluvastatin 61 Genz # 61 intracoronary 61 R# #mg BID 61 EXPAREL ™ 61 Phase IIb trial 61 Secondary endpoints include 61 QT QTc 61 ZYBRESTAT TM 61 Augment Injectable 61 romidepsin 61 sargramostim 61 IIa clinical 61 double blinded randomized 61 thymalfasin 61 DDP# 61 TMC# [002] 61 ATACAND 61 NLX P# 61 multicenter randomized 61 trial evaluating PRX# 61 gemcitabine Gemzar ® 61 ProSavin 61 Vascugel 61 HCD# [002] 61 undetectable HBV DNA 61 ILLUMINATE 61 virus HCV protease inhibitor 61 BCX# 61 TG# [001] 61 multicenter trials 61 Kamada AAT 61 EchoCRT 61 favorable pharmacokinetic 61 mg kg BID 61 substudy 61 Presents Preclinical 61 L PPDS 61 bicifadine 61 DASISION 61 Phase 2b randomized 61 Sapacitabine 61 Inhalation Solution 61 ENDEAVOR II 61 pharmacokinetic pharmacodynamic PK PD 61 ULORIC 61 Stedivaze 61 Blinatumomab 61 AST ALT 61 atacicept 61 edoxaban 61 evaluating mipomersen 61 TH# [003] 61 Secondary endpoints 61 longitudinal cohort study 61 ORENCIA ® 61 velafermin belinostat 61 TriRima 61 TAXUS V 61 SPIRIT III 61 selective androgen receptor modulator 61 Phase III VISTA 61 favorable tolerability 61 posaconazole 61 Bicifadine 61 ANG# 61 Hsp# Inhibitor 61 pitavastatin 61 PROMACTA 61 multicenter multinational 61 antithrombotic 61 Vascugel ® 61 candesartan cilexetil 61 metaglidasen 61 Solorel TM 61 budesonide MMX 61 Aclidinium 61 radiolabeled 61 evaluating REVLIMID 61 cariprazine 61 PROactive study 61 TLK# 61 liposomal amphotericin B 61 Virulizin R 61 pan HDAC inhibitor 61 KB# [002] 61 reactogenicity 61 RHUCIN 61 Safinamide 61 pramlintide metreleptin combination 61 Alocrest 61 By JENNIFER LEARN 61 Degarelix 61 selective agonist 61 tipifarnib 61 Phase 2a clinical trials 61 BiTE antibody MT# 61 Pimavanserin 61 Pivotal Phase 61 PCK# 61 ZD# [001] 61 Oral Fingolimod 61 AAG geldanamycin analog 61 OHR/AVR# 61 PEG IFN 61 arzoxifene 61 humanized anti 61 RenalGuard System TM 61 Afatinib 61 Aflibercept 61 Hemospan R 61 #th Annual Interscience 61 NeuroSTAT ® 61 ARIKACE 61 randomized controlled clinical 61 mapatumumab 61 TRANSFORMS 61 Tanespimycin 61 HF ACTION 61 standard chemotherapy regimen 61 relapsed MCL 61 deforolimus 61 bevacizumab Avastin ® 61 NEUVENGE 61 hyperphenylalaninemia HPA due 61 PRECISE trial 61 HDAC Inhibitor 61 multicenter randomized double 61 prospective observational 61 placebo controlled randomized 61 multicenter randomized Phase 61 gefitinib Iressa 61 intermittent dosing 61 #th Interscience Conference 61 NATRECOR ® 61 prospective randomized placebo 61 Exelixis compounds 61 Phase 2b clinical trials 61 AEGR 61 Adalimumab 61 CAMMS# 61 inecalcitol 61 Catena ® 61 coadministration 61 Controlled Trial 61 HER2 expression 61 APEX PD 61 COPERNICUS 61 Randomized controlled 61 vemurafenib 61 ImmuKnow 61 BAY #-# 61 IMGN# 61 radezolid 61 retrospective cohort 61 Zoraxel 61 Eluting Stent 61 perifosine KRX 61 AVERROES 61 anticancer compound 61 zotarolimus eluting stent 61 brivaracetam 61 RezularTM 61 PEG PAL 61 MoxDuo TM IR 61 Phase 2b Study 61 liposomal doxorubicin 61 rALLy clinical trial 61 XL# inhibits 61 glatiramer acetate 61 BNC# 61 #I TM# 61 BENICAR HCT 61 platelet inhibitor 61 REMINYL ® 61 MYDICAR ® 61 triphendiol 61 Cardiac Allograft Rejection 61 Randomized Phase II 61 urocortin 2 61 nucleotide analog 61 immune modulatory 61 Omacetaxine 61 CALGB 61 MoxDuo ® IR 61 oral iron chelator 61 AZILECT ® 61 celgosivir 61 Luteinizing Hormone Releasing Hormone 61 BETAS 60 Maximum Tolerated Dose MTD 60 Board DSMB 60 Novolimus 60 CUSTOM III 60 AIR CF1 60 QD dosing 60 severe gastroparesis 60 Placebo Controlled Trial 60 GRAVITAS trial 60 isatoribine 60 Clolar ® 60 PROSTVAC ® 60 eculizumab 60 clinico pathological 60 tubulin inhibitor 60 Solorel 60 virologic 60 ruboxistaurin 60 receptor inhibitor 60 CA9 SCAN 60 LSI #P 60 refractory prostate cancer 60 vismodegib 60 IMPACT IMmunotherapy 60 immune modulating 60 inhaled AAT 60 Tiotropium 60 Cardiotoxicity 60 azilsartan medoxomil 60 Dasatinib 60 alemtuzumab MS 60 clinical endpoints 60 NGX# 60 EmbraceAC 60 adalimumab 60 SPIRIT IV 60 Omacetaxine mepesuccinate 60 RGB # 60 plasma uric acid 60 diarrhea predominant irritable 60 GORE VIABAHN Endoprosthesis 60 peginesatide 60 antiangiogenic agent 60 serum cortisol 60 lenalidomide dexamethasone 60 romiplostim 60 Epanova 60 genotypic 60 LCP Tacro 60 enoximone 60 European Sepsis Trial 60 SUTENT ® 60 florbetaben 60 relapsed refractory multiple myeloma 60 null responder 60 oral methylnaltrexone 60 interferon gamma 1b 60 cancer mCRC 60 eculizumab therapy 60 EOquin 60 BLA submission 60 cinacalcet 60 Hyphanox 60 TO AVOID PREGNANCY WHILE 60 MADIT II 60 Trodusquemine 60 vandetanib 60 prostate cancer PCa 60 Metabolic Efficiency 60 Phase III confirmatory 60 USL# 60 apremilast 60 retrospective observational study 60 Natalizumab 60 atrasentan 60 cMET 60 ARCOXIA 60 CLL8 60 LCP AtorFen 60 Universal Flu Vaccine 60 TRO# 60 Phase IIb 60 orBec 60 Dose escalation 60 AQ4N 60 Solid Tumors 60 plasma kallikrein inhibitor 60 Pivotal Study 60 TRX1 60 tumor lysis syndrome 60 mGluR2 NAM 60 AIR CF2 60 dose dose escalation 60 REVLIMID lenalidomide 60 BrachySil TM 60 ACTEMRA TM 60 specified secondary endpoints 60 JAK2 inhibitor 60 Fx #A 60 torezolid 60 eltrombopag 60 RLY# 60 APOPTONE 60 subcutaneous formulation 60 Tyrosine Kinase Inhibitor 60 virological response 60 CYT# potent vascular disrupting 60 bepotastine besilate nasal spray 60 somatostatin analog 60 imatinib resistant 60 VNP#M 60 CCR9 60 aleglitazar 60 Genasense ® oblimersen 60 Phase 2a Study 60 Dose Response 60 anti amnesic 60 lead Aganocide compound 60 antitumor efficacy 60 genotypic resistance 60 BEXXAR Therapeutic Regimen 60 Teriflunomide 60 Ereska 60 metastatic renal cell carcinoma 60 HoFH 60 MVA MUC1 IL2 60 optimal dosing 60 DU #b 60 Triapine 60 longitudinal observational study 60 Interferon beta 1a 60 ZK EPO 60 Pharmacodynamics 60 Phase IIb Clinical Trial 60 treatment naive genotype 60 angiogenesis inhibitor 60 TELCYTA 60 Darusentan 60 AZOR 60 ara C 60 trospium 60 ascending doses 60 Insulin PH# 60 alicaforsen enema 60 bortezomib Velcade 60 Oral NKTR 60 aminotransferase 60 morphometric vertebral fractures 60 GRN#L 60 multicentre 60 Radezolid 60 PEGylated interferon beta 1a 60 β blockers 60 Proxinium TM 60 EndoTAG TM -1 60 Neuropsychiatric Inventory NPI 60 Androxal ® 60 CorVue ™ 60 HuLuc# 60 eTag assays 60 thalidomide Thalomid 60 HIF PH inhibitors 60 colorectal liver metastases 60 Randomized Double Blind Placebo 60 TREDAPTIVE 60 tolvaptan 60 VADT 60 farletuzumab 60 Phase 1b dose escalation 60 CB2 selective receptor agonist 60 DCCR 60 Carotid Revascularization Endarterectomy vs. 60 omega interferon 60 Multaq R 60 GAMMAGARD LIQUID 60 LCP Tacro ™ 60 S/GSK# 60 ovarian carcinoma 60 omecamtiv mecarbil 60 TBC# 60 Phase III 60 Phase 2b Trial 60 vitro experiments 60 efficacy 60 Azixa 60 PI3K inhibitor 60 decitabine 60 metastatic castration resistant 60 MET amplification 60 adenoma recurrence 60 unblinded 60 Perforomist ™ Inhalation Solution 60 CardioPET 60 papillary renal cell carcinoma 60 colesevelam HCl 60 secondary efficacy endpoint 60 XIENCE V Everolimus Eluting 60 paclitaxel eluting stents 60 cortical stimulation 60 HCV NS5B polymerase 60 azacytidine 60 novel oral anticoagulant

Back to home page